| Ticker Details |
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
|
| IPO Date: |
December 22, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$12.49B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.90 | 1.96%
|
| Avg Daily Range (30 D): |
$0.99 | 1.32%
|
| Avg Daily Range (90 D): |
$1.08 | 1.40%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.21M |
| Avg Daily Volume (30 D): |
1.44M |
| Avg Daily Volume (90 D): |
1.73M |
| Trade Size |
| Avg Trade Size (Sh.): |
81 |
| Avg Trade Size (Sh.) (30 D): |
57 |
| Avg Trade Size (Sh.) (90 D): |
59 |
| Institutional Trades |
| Total Institutional Trades: |
12,291 |
| Avg Institutional Trade: |
$2.94M |
| Avg Institutional Trade (30 D): |
$5.46M |
| Avg Institutional Trade (90 D): |
$5.96M |
| Avg Institutional Trade Volume: |
.06M |
| Avg Institutional Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.08M |
| Avg Closing Trade (30 D): |
$22.73M |
| Avg Closing Trade (90 D): |
$21.85M |
| Avg Closing Volume: |
148.92K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-1.99
|
$-.56
|
$-1.41
|
|
Diluted EPS
|
$-2.07
|
$-.56
|
$-1.41
|
|
Revenue
|
$1.06B
|
$246.09M
|
$203.33M
|
|
Gross Profit
|
$1.04B
|
$243.11M
|
$195.37M
|
|
Net Income / Loss
|
$154.57M
|
$-92.53M
|
$-229.39M
|
|
Operating Income / Loss
|
$-352.25M
|
$-117.42M
|
$-214.46M
|
|
Cost of Revenue
|
$17.43M
|
$2.98M
|
$7.96M
|
|
Net Cash Flow
|
$-91.14M
|
$-198.74M
|
$33.96M
|
|
PE Ratio
|
|
|
|
|
|
|